| Project/Area Number |
25670053
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
ISHIKAWA Minoru 東京大学, 分子細胞生物学研究所, 准教授 (70526839)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 多重薬理作用 / 創薬化学 |
|---|
| Outline of Final Research Achievements |
Hapariris C is an infectious disease caused by the hepatitis C virus (HCV). Standard of care for hepatitis C, the combination therapy with peginterferon and ribavirin, is the most effective for HCV genotype 1. Recently, HCV protease inhibitors have been also approved, but it is still important to establish new regimens for HCV patients.
We aimed to discover a novel strategy for the treatment of hepatitis C with polypharmacological approach. Two approaches were investigated. One was modulation of the functions of the target proteins of human origin by a small molecule, and the other was both inhibition and decrease of the target protein of HCV origin by a small molecule. As a result, we obtained lines of basic and useful information for the preparation of the target compounds.
|
